¶ Autoimmune Encephalitis
¶ Introduction
Autoimmune Encephalitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ Overview
Autoimmune encephalitis (AE) is a group of inflammatory brain diseases[1] in which the body's immune system produces antibodies that target neuronal cell-surface proteins[4], [synaptic receptors[/mechanisms/[synaptic-transmission[/mechanisms/[synaptic-transmission[/mechanisms/[synaptic-transmission--TEMP--/mechanisms)--FIX--, or intracellular antigens, leading to brain inflammation, cognitive dysfunction, seizures, and psychiatric disturbances. Once considered rare, AE is now recognized as a major cause of encephalitis[3], with a prevalence comparable to that of infectious encephalitis ([Dubey et al., 2018]https://doi.org/10.7326/M17-1905)). The discovery of anti-[NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor--TEMP--/mechanisms)--FIX-- encephalitis by Josep Dalmau in 2007 transformed the field, revealing that many cases previously diagnosed as psychiatric illness or "encephalitis of unknown etiology" were in fact autoimmune in nature (Dalmau et al., 2007).
AE shares important pathological features with [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases, including [neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX--, synaptic dysfunction, and, in severe or chronic cases, progressive neuronal loss and brain atrophy. Understanding AE has provided critical insights into the roles of [microglia[/entities/microglia.[/entities/microglia.[/entities/microglia.--TEMP--/entities)--FIX--.).)
¶ Epidemiology
The incidence of autoimmune encephalitis is estimated at 0.8–1.2 per 100,000 person-years, with prevalence approximately 13.7 per 100,000 — comparable to infectious encephalitis (11.6 per 100,000) (Dubey et al., 2018). The incidence has increased over time, from 0.4 per 100,000 (1995–2005) to 1.2 per 100,000 (2006–2015), largely attributable to improved recognition and expanded antibody testing (Dubey et al., 2018).
Key epidemiological features:
- Age: Anti-NMDAR encephalitis predominantly affects young women (median age ~21 years), while anti-LGI1 and anti-CASPR2 encephalitis typically present in older adults (median age ~60 years) (Graus et al., 2016)
- Gender: Anti-NMDAR encephalitis has a strong female preponderance [4]:1 female-to-male ratio), while anti-LGI1 encephalitis shows a male predominance [2]:1) (Titulaer et al., 2013)
- Racial disparities: Higher incidence and prevalence among African Americans (2.8/100,000 incidence, 38.3/100,000 prevalence) compared to Caucasians (Dubey et al., 2018)
- Paraneoplastic association: Up to 40–50% of anti-NMDAR encephalitis cases are associated with ovarian teratomas, particularly in young women (Titulaer et al., 2013)
¶ Classification
Autoimmune encephalitis is classified based on the target antigen and its location:
¶ Antibodies to Neuronal Cell-Surface Antigens
These antibodies directly disrupt receptor function through internalization, blocking, or cross-linking. They are generally associated with better treatment response and outcomes.
Anti-[NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor--TEMP--/mechanisms)--FIX-- Receptor] Encephalitis
The most common form of AE, accounting for approximately 50% of all seropositive cases. Antibodies target the GluN1 subunit of the [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor--TEMP--/mechanisms)--FIX-- receptor], causing receptor internalization and reduced [glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate--TEMP--/entities)--FIX-- signaling. The typical clinical presentation progresses through stages: psychiatric symptoms → seizures → movement disorders → autonomic dysfunction → decreased consciousness (Dalmau et al., 2011).
Anti-LGI1 Encephalitis
The second most common subtype (~27% of cases), involving antibodies against leucine-rich glioma-inactivated 1 protein. LGI1 modulates AMPA receptor and voltage-gated potassium channel function. Patients typically present with limbic encephalitis, faciobrachial dystonic seizures (FBDS), and hyponatremia. Predominantly IgG4-mediated (van Sonderen et al., 2016).
Anti-CASPR2 Encephalitis
Accounts for approximately 10% of seropositive AE. Antibodies target contactin-associated protein-like 2. [Clinical features include limbic encephalitis, neuromyotonia, neuropathic pain, and Morvan syndrome (a combination of peripheral nerve hyperexcitability, encephalopathy, and dysautonomia) (Lancaster et al., 2011)).
Anti-GABA Receptor Encephalitis
Antibodies target GABA-A or GABA-B receptors. Anti-GABA-B receptor encephalitis (~5% of cases) presents with prominent seizures and limbic encephalitis, and is frequently associated with small cell lung cancer. Anti-GABA-A receptor encephalitis causes severe, refractory seizures and status epilepticus (Lancaster et al., 2010).
Anti-AMPAR Encephalitis
Antibodies to alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors cause limbic encephalitis with prominent psychiatric features. Often paraneoplastic, associated with lung, breast, or thymic tumors (Lai et al., 2009).
¶ Antibodies to Intracellular Antigens
These are typically paraneoplastic and associated with cytotoxic T-cell-mediated neuronal damage. Prognosis is generally poorer.
- Anti-Hu (ANNA-1): Associated with small cell lung cancer; causes encephalomyelitis, sensory neuropathy
- Anti-Yo (PCA-1): Associated with ovarian and breast cancer; causes cerebellar degeneration
- Anti-Ri (ANNA-2): Associated with breast cancer; causes opsoclonus-myoclonus
- Anti-CV2/CRMP5: Associated with small cell lung cancer and thymoma; causes encephalomyelitis
- Anti-Ma2: Associated with testicular germ cell tumors; causes limbic and brainstem encephalitis
¶ Pathophysiology
¶ Blood-Brain Barrier Disruption
[blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- ([blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- breakdown plays a critical role in AE pathogenesis, enabling peripheral antibodies and immune cells to access the central nervous system. [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- disruption is associated with perivascular [neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX-- involving both innate and adaptive immune cells, creating a feed-forward loop that perpetuates inflammation (Leypoldt et al., 2015).
¶ Antibody-Mediated Mechanisms
For cell-surface antibodies, pathogenic mechanisms include:
- Receptor internalization: Anti-NMDAR antibodies cause crosslinking and internalization of [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor[/mechanisms/[nmda-receptor--TEMP--/mechanisms)--FIX-- receptors], reducing surface receptor density and disrupting [synaptic function[/mechanisms/[synaptic-function[/mechanisms/[synaptic-function[/mechanisms/[synaptic-function--TEMP--/mechanisms)--FIX-- (Hughes et al., 2010)
- Complement activation: Some antibodies (particularly IgG1 and IgG3) activate the [complement system[/entities/[complement-system[/entities/[complement-system[/entities/[complement-system--TEMP--/entities)--FIX--, leading to neuronal injury
- Blocking of receptor function: Antibodies can directly block ligand binding or receptor signaling
- Disruption of protein-protein interactions: Anti-LGI1 antibodies disrupt the interaction between LGI1 and its binding partners ADAM22/23, affecting synaptic transmission
¶ neuroinflammation and Neurodegeneration
In chronic or undertreated AE, ongoing inflammation can lead to neurodegeneration. microglia](https://doi.org/10.1212/WNL.0000000000004173)). This bridges AE with classical neurodegenerative conditions.
¶ Clinical Presentation
¶ Acute Phase
Common presenting features include:
- Psychiatric symptoms: Psychosis, hallucinations, personality changes, anxiety, agitation (present in >80% of anti-NMDAR encephalitis)
- Cognitive dysfunction: Memory impairment, confusion, disorientation, reduced level of consciousness
- Seizures: Focal or generalized seizures, status epilepticus (common in anti-LGI1 and anti-GABA-B encephalitis)
- Movement disorders: Orofacial dyskinesias, choreoathetosis, dystonic posturing, faciobrachial dystonic seizures (FBDS)
- Autonomic dysfunction: Cardiac dysrhythmias, blood pressure instability, central hypoventilation
- Speech disturbances: Reduced verbal output progressing to mutism
¶ Chronic Phase and Neurodegeneration
Long-term complications can include (Finke et al., 2017):
- Progressive brain atrophy, particularly [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- volume loss
- Persistent cognitive deficits (memory, executive function)
- Chronic epilepsy
- Psychiatric sequelae (depression, anxiety, personality changes)
¶ Diagnosis
¶ Clinical Criteria
The 2016 clinical diagnostic criteria for possible autoimmune encephalitis require (Graus et al., 2016):
- Subacute onset (rapid progression
months) of working memory deficits, altered mental status, or psychiatric symptoms - At least one of: new focal CNS findings, seizures not explained by previous epilepsy, CSF pleocytosis, MRI features suggestive of encephalitis
- Reasonable exclusion of alternative causes
¶ Antibody Testing
- Serum and CSF testing: Both should be tested; CSF has higher sensitivity for anti-NMDAR antibodies, while serum may be more sensitive for anti-LGI1
- Cell-based assays: Gold standard for detecting antibodies to neuronal surface antigens
- Tissue-based assays: Used for screening with rodent brain tissue immunohistochemistry
- Seronegative AE: Up to 20% of cases meeting clinical criteria have no identifiable antibody
¶ Neuroimaging
MRI findings in AE include (Kelley et al., 2017):
- T2/FLAIR hyperintensities in medial temporal lobes (limbic encephalitis pattern)
- Normal MRI in up to 50% of anti-NMDAR encephalitis
- [basal ganglia[/brain-regions/[basalganglia[/brain-regions/[basalganglia[/brain-regions/[basalganglia--TEMP--/brain-regions)--FIX-- involvement, cortical and cerebellar changes
- Progressive brain atrophy in chronic cases
¶ Additional Investigations
- EEG: Extreme delta brush pattern (pathognomonic for anti-NMDAR encephalitis), generalized slowing, epileptiform discharges
- CSF: Lymphocytic pleocytosis, oligoclonal bands, elevated IgG index
- Tumor screening: CT/MRI of chest, abdomen, pelvis; ovarian ultrasound; PET-CT for occult malignancy
¶ Treatment
¶ First-Line Immunotherapy
Initial treatment should be started promptly, as early intervention is associated with significantly better outcomes (Titulaer et al., 2013):
- High-dose intravenous corticosteroids: Methylprednisolone 1 g/day for 3–5 days
- Intravenous immunoglobulin (IVIG): 0.4 g/kg/day for 5 days
- Plasmapheresis/plasma exchange: 5–7 exchanges
- Tumor removal: Essential in paraneoplastic cases (e.g., ovarian teratoma resection)
¶ Second-Line Immunotherapy
For patients who fail to improve within 2–4 weeks:
- Rituximab: Anti-CD20 monoclonal antibody targeting B cells (375 mg/m² weekly for 4 weeks)
- Cyclophosphamide: Alkylating immunosuppressant (750 mg/m² monthly)
- Combination rituximab + cyclophosphamide may be more effective than either alone
¶ Emerging Therapies
- Tocilizumab: Anti-IL-6 receptor antibody showing promise in refractory cases (Lee et al., 2021)
- Bortezomib: Proteasome inhibitor targeting antibody-producing plasma cells
- Low-dose interleukin-2: To expand regulatory T cells
- Intrathecal methotrexate: For severe refractory cases
- CAR-T cell therapy: Investigational; targeting CD19+ B cells in refractory AE
¶ Long-Term Maintenance
Maintenance immunosuppression (mycophenolate mofetil, azathioprine, or rituximab) is recommended for at least 2 years to prevent relapse, which occurs in approximately 12–25% of patients (Titulaer et al., 2013).
¶ Prognosis
Outcomes in AE depend heavily on the antibody type, early treatment initiation, and presence of underlying tumors:
- Anti-NMDAR encephalitis: Approximately 80% achieve good functional recovery (mRS ≤2) with treatment; recovery can take 18+ months (Titulaer et al., 2013)
- Anti-LGI1 encephalitis: Good response to immunotherapy, but chronic cognitive deficits, particularly in memory, may persist (van Sonderen et al., 2016)
- Intracellular antibody syndromes: Generally poorer prognosis due to T-cell-mediated neuronal destruction
- Mortality: 5–10% overall, higher in intracellular antibody syndromes and delayed treatment
Predictors of good outcome include early treatment initiation, no ICU admission, lack of tumors or early tumor removal, and young age (Titulaer et al., 2013).
¶ Relationship to Neurodegeneration
Autoimmune encephalitis shares features with and may predispose to neurodegenerative conditions (Dalmau & Bhatt, 2018):
- Shared targets: Autoantibodies target proteins implicated in neurodegeneration — [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor]] receptors (excitotoxicity in AD), LGI1 (hippocampal circuits), CASPR2 (axonal function), and DPPX (neuronal excitability)
- Hippocampal sclerosis: Prolonged anti-LGI1 or anti-NMDAR encephalitis can cause permanent hippocampal atrophy mimicking neurodegenerative mesial temporal sclerosis
- Cognitive sequelae: Up to 25% of autoimmune encephalitis patients have persistent cognitive deficits resembling early neurodegeneration, particularly in executive function and memory
- Paraneoplastic neurodegeneration: Anti-Hu, anti-Yo, and anti-DNER antibodies cause irreversible neuronal death through cytotoxic T cell-mediated mechanisms, representing true autoimmune neurodegeneration
- Differential diagnosis: Rapidly progressive dementia workup must include autoimmune encephalitis screening (CSF autoantibody panels) as it is a potentially treatable mimic of neurodegeneration (Graus et al., 2016)
¶ Background
The study of Autoimmune Encephalitis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ Conclusion
Autoimmune encephalitis represents a critical intersection of immunology and neurology, with significant implications for neurodegenerative disease research. Key takeaways include:
- Treatable mimicker: AE is a potentially reversible cause of cognitive decline that must be considered in rapidly progressive dementia workups
- Spectrum expansion: The spectrum of autoimmune encephalitis continues to expand with new antibody specificities being discovered
- Chronic sequelae: Even with successful treatment, many patients experience persistent cognitive deficits and are at risk for relapse
- Research implications: Understanding antibody-mediated neuronal dysfunction provides insights into synaptic plasticity, receptor trafficking, and neuroinflammation pathways relevant to neurodegenerative conditions
Early recognition and aggressive immunotherapy remain the cornerstone of management, with favorable outcomes achievable in the majority of patients who receive timely treatment.
¶ External Links
¶ See Also
-
[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- {
if (window.__nwRefTooltipBound) return;
window.__nwRefTooltipBound = true;
var tooltip = null;
function ensureTooltip() {
if (tooltip) return tooltip;
tooltip = document.createElement('div');
tooltip.id = 'nw-ref-tooltip';
tooltip.style.position = 'fixed';
tooltip.style.zIndex = '9999';
tooltip.style.maxWidth = '420px';
tooltip.style.padding = '8px 10px';
tooltip.style.background = '#111';
tooltip.style.color = '#fff';
tooltip.style.borderRadius = '6px';
tooltip.style.fontSize = '12px';
tooltip.style.lineHeight = '1.4';
tooltip.style.display = 'none';
tooltip.style.pointerEvents = 'none';
tooltip.style.boxShadow = '0 6px 18px rgba(0,0,0,0.25)';
document.body.appendChild(tooltip);
return tooltip;
}document.addEventListener('mouseover', function(e) {
var a = e.target.closest('a.ref-link');
if (!a) return;
var text = a.getAttribute('data-ref-text') || a.getAttribute('title');
if (!text) return;
var el = ensureTooltip();
el.textContent = text;
el.style.display = 'block';
});document.addEventListener('mousemove', function(e) {
if (!tooltip || tooltip.style.display !== 'block') return;
tooltip.style.left = (e.clientX + 12) + 'px';
tooltip.style.top = (e.clientY + 12) + 'px';
});document.addEventListener('mouseout', function(e) {
if (!tooltip) return;
if (e.target.closest('a.ref-link')) {
tooltip.style.display = 'none';
}
});
})();
¶ References
- [Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840-851. DOI)
- [Titulaer MJ, et al. Treatment and prognostic factors for long-term outcome in patients with anti-[NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor encephalitis. Lancet Neurol. 2013;12(2):157-165. DOI
- [Irani SR, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241-255. DOI)
- Rosenfeld MR, Dalmau J. Paraneoplastic disorders of the central and peripheral nervous systems. Oncology (Williston Park). 2010;24(7):632-640.
- [McKeon A, et al. CNS aquaporin-4 autoimmunity mimicking IDH-wildtype glioblastoma. Neurology. 2018;91(3):123-126. DOI)
- [Flanagan EP, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. JAMA Neurol. 2015;72(1):35-40. DOI)
- [Graus F, et al. Classification of paraneoplastic neurological syndromes. Lancet Neurol. 2021;20(9):665-677. DOI
- [Hachiya Y, et al. Autoimmune encephalitis associated with voltage-gated potassium channel-complex antibodies. Brain Dev. 2019;41(10):829-838. DOI)
- [Lee WJ, et al. Anti-LGI1 encephalitis: clinical manifestations and outcome. J Neurol Neurosurg Psychiatry. 2021;92(9):982-988. DOI)
- [Probasco JC, et al. Clinical reasoning: A 32-year-old woman with subacute encephalitis. Neurology. 2019;92(7):333-338. DOI)